WuXi Biologics Constructs Integrated Manufacturing Center In Chengdu

Published 6-2-2019
  • WuXi Biologics - Chengdu Integrated Manufacturing Center
  • WuXi Biologics - Chengdu Integrated Manufacturing Center

    Courtesy of WuXi Biologics.

WuXi Biologics began construction in May of 2019 on a 1.3 million-sf integrated manufacturing center in Chengdu, China. Meeting the criteria of both the U.S. Food and Drug Administration and the European Medicines Agency's GMP guidelines, the biologics hub will include both drug development and commercial manufacturing facilities. Offering an initial bioreactor capacity of 48,000 liters, the project is WuXi's twelfth drug substance manufacturing plant and will use the company's open-access and proprietary platforms.